Published in Aliment Pharmacol Ther on June 01, 2006
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
Identification of genes conferring resistance to 5-fluorouracil. Proc Natl Acad Sci U S A (2009) 1.92
Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol (2013) 1.60
Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. J Hematol Oncol (2008) 1.43
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist (2010) 1.35
Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol (2009) 1.31
Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract (2010) 1.31
Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol (2008) 1.26
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent) (2008) 1.20
A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol (2016) 1.16
Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int (2014) 1.15
A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol (2009) 1.12
Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther (2013) 1.11
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J Clin Invest (2012) 1.09
Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2011) 1.07
Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial-mesenchymal transition. J Cell Mol Med (2013) 1.06
The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS One (2013) 1.06
Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol Int (2008) 1.04
Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol (2012) 1.03
Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol (2010) 1.01
Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol Sin (2010) 0.95
Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer (2013) 0.95
High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma. J Transl Med (2013) 0.94
Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. Dig Dis Sci (2010) 0.94
Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. BMC Cancer (2011) 0.93
The transcription factor LSF: a novel oncogene for hepatocellular carcinoma. Am J Cancer Res (2012) 0.93
Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol (2015) 0.93
Current and future treatments for hepatocellular carcinoma. World J Gastroenterol (2015) 0.92
Herbal medicine and hepatocellular carcinoma: applications and challenges. Evid Based Complement Alternat Med (2011) 0.92
Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist (2012) 0.90
1, 25(OH)₂D₃ inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes. Curr Med Chem (2013) 0.90
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist (2014) 0.89
Survival after locoregional treatments for hepatocellular carcinoma: a cohort study in real-world patients. ScientificWorldJournal (2012) 0.89
Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography. BMC Cancer (2011) 0.87
Treatment of hepatocellular carcinoma with portal vein thrombosis by sorafenib combined with hepatic arterial infusion chemotherapy. Gut Liver (2010) 0.87
Independent factors and predictive score for extrahepatic metastasis of hepatocellular carcinoma following curative hepatectomy. Oncologist (2012) 0.86
Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma. ScientificWorldJournal (2013) 0.86
Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. Mol Cancer (2010) 0.86
Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma. Medicine (Baltimore) (2016) 0.86
Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget (2010) 0.84
Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy? J Gastrointest Cancer (2010) 0.84
Surgical strategy for liver cancers in the era of effective chemotherapy. Liver Cancer (2013) 0.84
Laparoscopic radiofrequency ablation of unresectable hepatocellular carcinoma: long-term follow-up. HPB (Oxford) (2008) 0.84
Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. World J Surg Oncol (2015) 0.83
Monopolar radiofrequency ablation using a dual-switching system and a separable clustered electrode: evaluation of the in vivo efficiency. Korean J Radiol (2014) 0.82
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. Clin Mol Hepatol (2015) 0.81
Cirrhosis and Chronic Viral Hepatitis as Risk Factors for Hepatocellular Carcinoma: Romanian Single-clinic Experience. Maedica (Buchar) (2010) 0.81
Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial. PLoS One (2013) 0.81
Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report. J Med Case Rep (2012) 0.81
Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. J Gastroenterol (2016) 0.80
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. Invest New Drugs (2011) 0.80
Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. Invest New Drugs (2011) 0.80
Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. J Gastroenterol (2016) 0.80
Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells. Invest New Drugs (2011) 0.78
The In Ovo Chick Chorioallantoic Membrane (CAM) Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma. J Vis Exp (2015) 0.78
A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma. Invest New Drugs (2011) 0.78
Comparison of epirubicin-iodized oil suspension and emulsion for transcatheter arterial chemoembolization in VX2 tumor. ScientificWorldJournal (2012) 0.77
Challenges of advanced hepatocellular carcinoma. World J Gastroenterol (2016) 0.77
Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med (2015) 0.76
β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1. Sci Rep (2016) 0.76
Effects of cordycepin on HepG2 and EA.hy926 cells: Potential antiproliferative, antimetastatic and anti-angiogenic effects on hepatocellular carcinoma. Oncol Lett (2014) 0.75
Long-term survival of patients with hepatocellular carcinoma with pulmonary and adrenal metastasis: A case report. Exp Ther Med (2012) 0.75
Embolotherapy in the management of hepatocellular carcinoma. Semin Intervent Radiol (2008) 0.75
Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience. Springerplus (2016) 0.75
A novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy. Oncotarget (2016) 0.75
Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral chemoimmunotherapy. J Hepatocell Carcinoma (2015) 0.75
New Biomarkers for Early Detection of Hepatocellular Carcinoma. EBioMedicine (2015) 0.75
Targeting Notch3 in Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Perspectives. Int J Mol Sci (2016) 0.75
Elevated ZC3H15 increases HCC growth and predicts poor survival after surgical resection. Oncotarget (2016) 0.75
Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report. Cases J (2009) 0.75
Targeting metastatic upper gastrointestinal adenocarcinomas. World J Clin Oncol (2011) 0.75
A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression. J Gastrointest Oncol (2014) 0.75
TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable pedunculated hepatocellular carcinoma. Medicine (Baltimore) (2017) 0.75
Systemic treatment of hepatocellular carcinoma: Past, present and future. World J Hepatol (2017) 0.75
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology (1998) 3.62
K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer (1997) 2.60
Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene (2011) 2.42
Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology (1994) 2.27
Chloroquine stabilizes pancreatic lysosomes and improves survival of mice with diet-induced acute pancreatitis. Pancreas (1997) 2.06
Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology (1996) 2.00
Meso-substituted cationic porphyrins as efficient photosensitizers of gram-positive and gram-negative bacteria. J Photochem Photobiol B (1996) 1.83
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene (2013) 1.55
Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology (2001) 1.53
New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene (2006) 1.52
The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Clin Cancer Res (2013) 1.47
[Prophylactic sclerosis of esophageal varices. Results of a controlled prospective study]. Med Clin (Barc) (1991) 1.37
Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer. Proc Natl Acad Sci U S A (2006) 1.36
Hepatocellular carcinoma. Br J Surg (1998) 1.35
Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology (2000) 1.35
Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer. Oncogene (2011) 1.31
Morphological criteria to distinguish cell death induced by apoptotic and necrotic treatments. Apoptosis (2005) 1.31
Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo. Oncogene (2006) 1.27
Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology (2000) 1.13
Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene (2011) 1.13
Fixation and permanent mounting of fluorescent probes after vital labelling of cultured cells. Acta Histochem (2001) 1.10
Recent advances in cancer therapy: an overview. Curr Pharm Des (2010) 1.10
PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. Br J Cancer (2008) 1.07
Sugar malabsorption in functional bowel disease: clinical implications. Am J Gastroenterol (1993) 1.06
Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res (1996) 1.03
Hepatocellular carcinoma: is surveillance cost effective? Gut (2001) 1.01
Antibodies to synthetic corticotrophin. Nature (1966) 0.98
[Study of the brachial plexus by magnetic resonance]. Rev Neurol (1998) 0.98
Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma? Eur Radiol (2006) 0.97
High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. Hepatology (2001) 0.97
Congenital fusion of the thalami (atresia of the third ventricle) and associated anomalies in a 6-months-old infant. Acta Neuropathol (1969) 0.96
Orthotopic models of human pancreatic cancer. Ann N Y Acad Sci (1999) 0.95
Routine tests of renal function, alcoholism, and nutrition improve the prognostic accuracy of Child-Pugh score in nonbleeding advanced cirrhotics. Am J Gastroenterol (1993) 0.93
A pseudoendocardium for implantable blood pumps. Trans Am Soc Artif Intern Organs (1966) 0.93
[Laparoscopic appendectomy after the learning curve]. Cir Pediatr (2008) 0.90
DCC and SMAD4 alterations in human colorectal and pancreatic tumor dissemination. Oncogene (2000) 0.90
Skeletal efficacy with parathyroid hormone in rats was not entirely beneficial with long-term treatment. J Pharmacol Exp Ther (2002) 0.88
Catalytic seawater flue gas desulfurization process: an experimental pilot plant study. Environ Sci Technol (2007) 0.88
Photodynamic damage to HeLa cell microtubules induced by thiazine dyes. Cancer Chemother Pharmacol (1996) 0.87
Porphycenes: facts and prospects in photodynamic therapy of cancer. Curr Med Chem (2007) 0.87
Short-chain PEG molecules strongly bound to magnetic nanoparticle for MRI long circulating agents. Acta Biomater (2013) 0.87
Improving extracellular production of food-use enzymes from Aspergillus nidulans. J Biotechnol (2002) 0.86
Motor function of the esophagus after caustic burn. Eur J Pediatr Surg (1996) 0.86
DNA methylation determines nucleosome occupancy in the 5'-CpG islands of tumor suppressor genes. Oncogene (2013) 0.86
Locoregional treatments for hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol (1999) 0.86
Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates. Transplant Proc (2005) 0.86
Effects of prednisolone and dexamethasone on alkali burns of the esophagus in rabbit. J Pediatr Gastroenterol Nutr (1996) 0.86
Multiple hereditary infundibulocystic basal cell carcinomas: a genodermatosis different from nevoid basal cell carcinoma syndrome. Arch Dermatol (1999) 0.85
Photodamage induced by Zinc(II)-phthalocyanine to microtubules, actin, alpha-actinin and keratin of HeLa cells. Photochem Photobiol (2001) 0.85
Enterogenous cyst of the ampulla of Vater. Digestion (1969) 0.83
Evaluation of reverse transcription and polymerase chain reaction (RT/PCR) for the detection of rotaviruses: applications of the assay. Res Virol (1997) 0.83
Low radiation and low-contrast dose pulmonary CT angiography: Comparison of 80 kVp/60 ml and 100 kVp/80 ml protocols. Clin Radiol (2012) 0.82
Hepatic hamartoma in a newborn. Pediatr Radiol (1980) 0.82
Role of fructose-sorbitol malabsorption in the irritable bowel syndrome. Gastroenterology (1991) 0.82
Congenital self-healing reticulohistiocytosis: report of a case and review of the literature. Acta Paediatr (2004) 0.82
Gaze estimation interpolation methods based on binocular data. IEEE Trans Biomed Eng (2012) 0.82
Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients. Eur J Clin Microbiol Infect Dis (1998) 0.82
Improving images of fluorescent cell labeling by background signal subtraction. Biotech Histochem (2009) 0.82
Effects of prednisolone and dexamethasone in children with alkali burns of the oesophagus. Eur J Pediatr Surg (1996) 0.82
Cortical bone dynamics measured by means of tetracycline labeling in 21 cases of osteoporosis. J Lab Clin Med (1966) 0.81
Photosensitizing dyes and fluorochromes as substitutes for 33258 Hoechst in the fluorescence-plus-Giemsa (FPG) chromosome technique. Histochemistry (1985) 0.80
Frequency-specific coupling in the cortico-cerebellar auditory system. J Neurophysiol (2008) 0.80
Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial. Gut (1996) 0.80
The current status of liver transplantation for primary hepatic malignancy. Clin Liver Dis (2000) 0.80
The cationic meso-substituted porphyrins: an interesting group of photosensitizers. J Photochem Photobiol B (1993) 0.80
Early detection of cancer: ideas for a debate. Crit Rev Oncol Hematol (2006) 0.80
A balloon-expandable intravascular stent for obliterating experimental aortic dissection. J Vasc Surg (1990) 0.80
Images in hepatology. Intrahepatic bleeding due to undifferentiated (embryonal) hepatic sarcoma. J Hepatol (2000) 0.80
Haversian bone formation rates determined by a new method in a mastodon, and in human diabetes mellitus and osteoporosis. Calcif Tissue Res (1970) 0.79
Pulmonary abscess as a complication of transarterial embolization of multinodular hepatocellular carcinoma. Am J Gastroenterol (1997) 0.79
Photodynamic effects of the cationic porphyrin, mesotetra(4N-methylpyridyl)porphine, on microtubules of HeLa cells. J Photochem Photobiol B (1995) 0.79
A study of interaction of thioflavine T with DNA: evidence for intercalation. Cell Mol Biol (1987) 0.79
Fluorescence microscopy of rat embryo sections stained with haematoxylin-eosin and Masson's trichrome method. J Microsc (1998) 0.79
Clear cell sarcoma of the abdominal wall with peritoneal sarcomatosis: CT features. Eur Radiol (1999) 0.79
Fluorescent porphyrin counterstaining of chromatin DNA in conjunction with immunofluorescence methods using FITC-labelled antibodies. J Microsc (1996) 0.79
Meso-tetraphenylporphyrin: photosensitizing properties and cytotoxic effects on cultured tumor cells. Int J Oncol (1998) 0.78
Arterial hypertension and extrinsic renal artery compression: case report. J Cardiovasc Surg (Torino) (1973) 0.78
ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. Int J Cancer (2013) 0.78
Necrotic cell death induced by photodynamic treatment of human lung adenocarcinoma A-549 cells with palladium(II)-tetraphenylporphycene. Int J Oncol (2004) 0.78
Approaching focal liver lesions. Rev Esp Enferm Dig (2004) 0.78
Next-generation sequencing: path for driver discovery in hepatocellular carcinoma. Gastroenterology (2012) 0.78
Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis. Oncogene (2016) 0.78
Improved detection of K-ras codon 12 mutations in fecal exfoliated cells. Lab Invest (1999) 0.78
[Adult living donor liver transplantation. Analysis of the first 30 cases]. Gastroenterol Hepatol (2003) 0.78
[Preliminary results of the relevance the sentinel node in head and neck tumors]. Acta Otorrinolaringol Esp (2003) 0.77
p53 in a thyroid follicular carcinoma with foci of poorly differentiated and anaplastic carcinoma. Pathol Res Pract (1996) 0.77
Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma. Aliment Pharmacol Ther (2003) 0.77
[Primary surgical pathology of the epiploon]. Cir Pediatr (1990) 0.77
[Predicted duration of protective anti-HBs antigens in Peruvian health care workers after six years of vaccination]. Rev Gastroenterol Peru (2002) 0.77
An artificial neural network model for predicting the subcellular localization of photosensitisers for photodynamic therapy of solid tumours. Curr Med Chem (2012) 0.77
Photosensitizing properties of palladium-tetraphenylporphycene on cultured tumour cells. Anticancer Drug Des (2000) 0.77
Uptake and photoeffectiveness of two thiazines in HeLa cells. Anticancer Drug Des (1993) 0.76
The pesticide malathion induces alterations in actin cytoskeleton and in cell adhesion of cultured breast carcinoma cells. Int J Oncol (2003) 0.76
Corrosion of pacemaker electrodes. Pacing Clin Electrophysiol (1981) 0.76
[Mesenterial lipoma in a child (author's transl)]. An Esp Pediatr (1979) 0.76
Anorectal atresia. An experimental model in the rat. Eur J Pediatr Surg (2001) 0.75
[Fever of unknown origin as the presenting form of an inflammatory pseudotumor of the spleen]. Med Clin (Barc) (1995) 0.75
[Phimosis]. An Pediatr (Barc) (2004) 0.75